Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boulder/denver blog main
boulder/denver top stories
crispr
6
×
detroit blog main
detroit top stories
fda
6
×
life sciences
national
6
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
indiana blog main
indiana top stories
ipo
eli lilly
glaxosmithkline
cancer
clinical trials
editas medicine
gene editing
medical devices
novartis
sanofi
startups
What
bio
roundup
crispr
new
ceo
ipo
life
month
moves
science
therapeutics
week
years
acquisitions
allogene
announced
bails
big
biopharma
black
bosley's
bosley’s
brand
bridge
bridgebio
bucks
cancer
capital
car
cas
collabs
companies
congress
congressional
continue
covid
crime
daniel
deal
debut
Language
unset
Current search:
crispr
×
national
×
fda
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More